Refemoline 0.1%+0.025%

Refemoline 0.1%+0.025% | INDICATIONS AND USES

This preparation eye drop is indicated in-

Acute and chronic allergic non-infectious conjunctivitis and keratitis with severe swelling and intravascular injection
Non-infectious inflammation of the anterior segment of the eye (including anterior uveitis, episcleritis and scleritis)
Post-operative irritative conditions after strabismus; cataract & glaucoma surgery with supplementary antimicrobial therapy.

Refemoline 0.1%+0.025% | PHARMACOLOGY

Fluorometholone is thought to act by the induction of phospholipase A2 inhibitory proteins which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. On the other hand, Tetrahydrozoline is an alpha agonist which constricts the conjunctival blood vessels and thereby relieves the redness of the eye.

Refemoline 0.1%+0.025% | DOSAGE & ADMINISTRATION

Use in adult: Instill 1 drop into the conjunctival sac 2-3 times daily. The dose may be increased for severe and adult patient to 1 drop hourly for first one to two days.Use in children: Safety & effectiveness in children below 2 years of age have not been established.

Refemoline 0.1%+0.025% | DRUG INTERACTIONS

Tetrahydrozoline may interact with antidepressant drugs which inhibits Mono Amino Oxidase (MAO) Enzyme such as Isocarboxazid, phenelzine and its sulphate derivative, Toloxatone, Tranylcypromine and its sulphate derivative etc.

Refemoline 0.1%+0.025% | SIDE EFFECTS

Mild burning sensation, reversible increase in intraocular pressure, reactive hyperemia, cataract & corneal defects, glaucoma, systemic effects (chronic use).

Refemoline 0.1%+0.025% | USE DURING PREGNANCY AND LACTATION

There are no adequate and well-controlled studies of Fluorometholone & Tetrahydrozoline in pregnancy or while breast-feeding. Therefore, this combination should be used during pregnancy only if the potential benefits justify the potential risk to the fetus.

Refemoline 0.1%+0.025% | PRECAUTIONS & WARNINGS

Avoid prolonged use. This preparation should be used after a careful risk benefit evaluation in case of patients with severe blood circulation diseases, metabolic disturbances, under treatment with MAOIs & other potentially hypertensive drugs, history of cataract, herpes simplex infection, rhinitis sicca.

Refemoline 0.1%+0.025% | THERAPEUTIC CLASS

Ophthalmic Steroid preparations

Refemoline 0.1%+0.025% | STORAGE CONDITIONS

Keep out of the reach of children. Store in a cool, dry place, away from heat and direct light. Do not use more than 4 weeks after opening.